Almirall (ALM)

12.890
+0.115(+0.90%)
  • Volume:
    199,599
  • Bid/Ask:
    12.810/12.970
  • Day's Range:
    12.725 - 12.890
  • Type:Equity
  • Market:Spain
  • ISIN:ES0157097017

ALM Overview

Prev. Close
12.89
Day's Range
12.725-12.89
Revenue
1.22B
Open
12.735
52 wk Range
8.714-15.35
EPS
0.32
Volume
199,599
Market Cap
2.3B
Dividend (Yield)
0.19
(1.30%)
Average Vol. (3m)
346,965
P/E Ratio
47.46
Beta
0.46
1-Year Change
35.37%
Shares Outstanding
179,776,802
Next Earnings Date
Nov 15, 2021
What is your sentiment on Almirall?
or
Market is currently closed. Voting is open during market hours.

Almirall News

Almirall Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Buy
SummaryStrong BuyStrong BuyStrong BuySellStrong Buy

Almirall Company Profile

Almirall Company Profile

Employees
1785
Market
Spain

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for the central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Read More
  • Next level is around 12 euros. Will big funds invest in this company? The financial reports are strong low debt, enough income...
    0
    • almirall almirall, almirall te quiero, lala lala lararala
      0
      • cambia tendencia o sigue hacia abajo? hay fondos entrando?
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.